Compare LMRI & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMRI | QURE |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2025 | 2007 |
| Metric | LMRI | QURE |
|---|---|---|
| Price | $14.44 | $25.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $22.67 | ★ $58.55 |
| AVG Volume (30 Days) | 621.0K | ★ 1.7M |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,003,375,000.00 | $15,751,000.00 |
| Revenue This Year | $9.29 | N/A |
| Revenue Next Year | $5.01 | $142.93 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.38 | N/A |
| 52 Week Low | $14.00 | $7.76 |
| 52 Week High | $19.45 | $71.50 |
| Indicator | LMRI | QURE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.62 |
| Support Level | N/A | $21.64 |
| Resistance Level | N/A | $23.34 |
| Average True Range (ATR) | 0.00 | 1.72 |
| MACD | 0.00 | 0.36 |
| Stochastic Oscillator | 0.00 | 51.64 |
Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities including MRIs, CT scans, PET scans, X-rays, ultrasounds, and mammography. Its products and operations are managed and reported in two operating segments: Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The professional services segment generates revenue from interpreting imaging studies conducted by other parties, mainly hospital imaging departments. The majority of revenue is generated from the Outpatient segment, which generates revenue by performing imaging studies and providing radiologists' interpretations of those studies.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.